Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone.

J Am Heart Assoc · 2025 · PMC12748066 · PMID 40820974

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

For stenosis degree, evolocumab add‐on therapy showed a significant percentage reduction in the nonintensive statin group (estimate [95% CI], −33.1% [−54.0%, −12.1%]), while a nonsignificant trend toward reduction was observed in the intensive statin group (−14.6% [−31.0%, 2.5%]).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.